NEW YORK, NY / ACCESSWIRE / September 20, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of PTC Therapeutics, Inc. ("PTC" or "the Company") (NASDAQ:PTCT). Investors who purchased PTC securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/ptct.
![](https://www.accesswire.com/users/newswire/images/786080/bron.png)
The investigation concerns whether PTC has violated federal securities laws.
Investigation Details:
On September 15, 2023, PTC issued a press release "announc[ing] . . . that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarnaâ„¢ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization." On this news, PTC's stock price fell $11.13 per share, or 29.77%, to close at $26.26 per share on September 15, 2023.
What's Next?
If you are aware of any facts relating to this investigation or purchasedPTC securities, you can assist this investigation by visiting the firm's site: www.bgandg.com/ptct. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
332-239-2660 | [email protected]
SOURCE: Bronstein, Gewirtz and Grossman, LLC